Liquid Biopsy: Accelerate Your Circulating Biomarker Research

Liquid biopsy is an innovative, non-invasive diagnostic technique that enables the detection of circulating tumor cells (CTCs) and molecular biomarkers in various body fluids, including blood and urine. This approach is especially valuable in clinical scenarios where traditional tissue biopsies are challenging or impractical. For instance, it proves beneficial when tissue samples are limited, when the available samples contain insufficient tumor material, or when tumors are located in areas that are difficult to access. It also supports longitudinal disease monitoring, MRD assessment and early detection efforts.

Despite its promise, the widespread adoption of liquid biopsy has been hindered by several technical and logistical challenges. These include the low sensitivity and specificity of current detection methods, the absence of standardized protocols across laboratories, and issues related to scalability for broader clinical use.

Discover how our end-to-end and automation-ready comprehensive liquid biopsy workflow is designed to overcome many of these obstacles. By streamlining the process from sample collection to data interpretation, our solution empowers researchers and clinicians to move seamlessly from discovery to actionable insights, enhancing the potential of liquid biopsy in precision medicine.